Search results
Results from the WOW.Com Content Network
Pregnancy-induced hypercoagulability is probably a physiologically adaptive mechanism to prevent post partum hemorrhage. [1] Pregnancy changes the plasma levels of many clotting factors, such as fibrinogen, which can rise up to three times its normal value. [2] Thrombin levels increase. [3] Protein S, an anticoagulant, decreases.
Antithrombin III deficiency (abbreviated ATIII deficiency) is a deficiency of antithrombin III.This deficiency may be inherited or acquired. [1] It is a rare hereditary disorder that generally comes to light when a patient suffers recurrent venous thrombosis and pulmonary embolism, and repetitive intrauterine fetal death (IUFD). [2]
Direct factor Xa inhibitors (xabans) are anticoagulants (blood thinning drugs), used to both treat and prevent blood clots in veins, and prevent stroke and embolism in people with atrial fibrillation (AF).
FX antigen and its coagulant activity can be used to classify the severity of the condition: [4] Type I has low levels of FX antigen and activity. Type II has low coagulant activity but normal or borderline FX antigen levels. The FX (F10) gene is found on chromosome 13q34. [2] Heterogeneous mutations have been described in FX deficient patients.
Results are given in units/mL of anti-factor Xa, such that high values indicate high levels of anticoagulation and low values indicate low levels of anticoagulation in the plasma sample. [ 17 ] LMWHs have a targeted therapeutic window of approximately 0.6–1.2 IU/ml. LMWH has a potency of 70 units/mg of anti-factor Xa activity and a ratio of ...
This study reports results on 352 people and demonstrates a reduction of anti-Xa-activity while also showing an excellent or good hemostatic efficacy in 82%. While people who were expected to die in 30 days were excluded from the study, 14% of participants died. There was no relationship between hemostatic efficacy and reduced anti-Xa-activity ...
Use is not recommended during pregnancy or breastfeeding. [1] [9] Use appears to be relatively safe in those with mild kidney problems. [9] Compared to warfarin it has fewer interactions with other medications. [12] It is a direct factor Xa inhibitor. [8] In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an ...
In coagulation, the coagulation factor X can be activated into factor Xa in two ways: either extrinsically or intrinsically. The activating complexes are together called tenase . Tenase is a blend word of "ten" and the suffix "-ase", which means, that the complex activates its substrate (inactive factor X) by cleaving it.